Sopharma AD (WSE:SPH)

Market Cap	4.01B +94.8%
Revenue (ttm)	5.47B +22.1%
Net Income	270.79M +50.2%
EPS	0.97 +183.9%
Shares Out	n/a
PE Ratio	14.82
Forward PE	n/a
Dividend	0.36 (2.85%)
Ex-Dividend Date	Dec 18, 2025

Volume	2,082
Average Volume	816
Open	12.55
Previous Close	12.55
Day's Range	12.55 - 12.55
52-Week Range	3.80 - 16.00
Beta	-0.13
RSI	68.34
Earnings Date	Jan 30, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1933
• Employees: 5,905
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SPH

Financial Performance

In 2024, Sopharma AD's revenue was 2.14 billion, an increase of 13.27% compared to the previous year's 1.89 billion. Earnings were 77.85 million, a decrease of -18.89%.

Financial numbers in BGN